Your browser doesn't support javascript.
loading
A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.
Schön, Jacob; Barut, G Tuba; Trüeb, Bettina Salome; Halwe, Nico Joel; Berenguer Veiga, Inês; Kratzel, Annika; Ulrich, Lorenz; Kelly, Jenna N; Brügger, Melanie; Wylezich, Claudia; Taddeo, Adriano; Aguiar Moreira, Etori; Túrós, Demeter; Grau-Roma, Llorenç; Ahrens, Ann Kathrin; Schlottau, Kore; Britzke, Tobias; Breithaupt, Angele; Corleis, Björn; Kochmann, Jana; Oliveira Esteves, Blandina I; Almeida, Lea; Thomann, Lisa; Devisme, Christelle; Stalder, Hanspeter; Steiner, Silvio; Ochsenbein, Sarah; Schmied, Kimberly; Labroussaa, Fabien; Jores, Jörg; V'kovski, Philip; Cmiljanovic, Vladimir; Alves, Marco P; Benarafa, Charaf; Ebert, Nadine; Hoffmann, Donata; Beer, Martin; Thiel, Volker.
Afiliação
  • Schön J; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Barut GT; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Trüeb BS; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Halwe NJ; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Berenguer Veiga I; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Kratzel A; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Ulrich L; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Kelly JN; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Brügger M; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Wylezich C; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Taddeo A; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Aguiar Moreira E; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Túrós D; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Grau-Roma L; Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland.
  • Ahrens AK; European Virus Bioinformatics Center, Jena, Germany.
  • Schlottau K; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Britzke T; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Breithaupt A; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Corleis B; Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Kochmann J; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Oliveira Esteves BI; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Almeida L; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Thomann L; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Devisme C; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Stalder H; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Steiner S; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Ochsenbein S; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Schmied K; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Labroussaa F; Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Jores J; Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • V'kovski P; Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Cmiljanovic V; Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Alves MP; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Benarafa C; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Ebert N; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Hoffmann D; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Beer M; Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Thiel V; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Nat Microbiol ; 9(8): 2099-2112, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38997518
ABSTRACT
Approved vaccines are effective against severe COVID-19, but broader immunity is needed against new variants and transmission. Therefore, we developed genome-modified live-attenuated vaccines (LAV) by recoding the SARS-CoV-2 genome, including 'one-to-stop' (OTS) codons, disabling Nsp1 translational repression and removing ORF6, 7ab and 8 to boost host immune responses, as well as the spike polybasic cleavage site to optimize the safety profile. The resulting OTS-modified SARS-CoV-2 LAVs, designated as OTS-206 and OTS-228, are genetically stable and can be intranasally administered, while being adjustable and sustainable regarding the level of attenuation. OTS-228 exhibits an optimal safety profile in preclinical animal models, with no side effects or detectable transmission. A single-dose vaccination induces a sterilizing immunity in vivo against homologous WT SARS-CoV-2 challenge infection and a broad protection against Omicron BA.2, BA.5 and XBB.1.5, with reduced transmission. Finally, this promising LAV approach could be applicable to other emerging viruses.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Atenuadas / Genoma Viral / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Animals / Female / Humans Idioma: En Revista: Nat Microbiol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Atenuadas / Genoma Viral / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Animals / Female / Humans Idioma: En Revista: Nat Microbiol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha